InventisBio (Shanghai) Co., Ltd. (SHA: 688382) announced FDA clearance to initiate a Phase II clinical study for D-2570, an oral TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis. The multicenter, randomized, double-blind, placebo-controlled trial positions InventisBio in the competitive oral immunology space, targeting the same pathway as Bristol Myers Squibb’s approved Sotyktu (deucravacitinib).
U.S.-first development signals global ambition; China NMPA filing likely to follow positive Phase II data
Competitive Landscape
Nimbus (TAK-279), Ventyx (VTX958), and Sotyktu generics in development; D-2570 needs superiority or best-in-class profile to differentiate
Development Timeline: Phase II enrollment Q2 2026; data readout H2 2027; potential Phase III initiation 2028 if PASI 90 rates competitive with Sotyktu (~50–60%)
Commercial Potential: Peak sales $300–500 million globally if approved; China market adds RMB 500+ million opportunity
Forward‑Looking Statements This brief contains forward‑looking statements regarding clinical enrollment, efficacy outcomes, and regulatory pathways for D-2570. Actual results may differ due to competitive dynamics with established TYK2 inhibitors, dose optimization challenges, and reimbursement negotiations in the psoriasis market.-Fineline Info & Tech
